Quratis Inc. (KOSDAQ:348080)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,207.00
-60.00 (-4.74%)
At close: Mar 9, 2026
106.32%
Market Cap 98.72B
Revenue (ttm) 2.28B
Net Income (ttm) -24.09B
Shares Out 81.79M
EPS (ttm) -370.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 936,784
Average Volume 425,664
Open 1,450.00
Previous Close 1,267.00
Day's Range 1,205.00 - 1,450.00
52-Week Range 516.00 - 2,095.00
Beta -0.72
RSI 58.04
Earnings Date n/a

About Quratis

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 348080
Full Company Profile

Financial Performance

In 2024, Quratis's revenue was 373.80 million, a decrease of -63.71% compared to the previous year's 1.03 billion. Losses were -26.27 billion, 54.6% more than in 2023.

Financial Statements

News

There is no news available yet.